XORTX Patent Allowed for XRx-101 Program by Japan Patent Office

Japan Patent Office allows claims directed to xanthine oxidase inhibitor compositions for acute kidney injury and other health consequences of viral infection; once registered, patent expected to remain in force until March 2041 Japan Patent Office allows claims directed to xanthine oxidase inhibitor compositions for acute kidney injury and other health consequences of viral infection; once registered, patent expected to remain in force until March 2041

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.